Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib)
Shots:
- Puma to receive upfront- milestones up to $7.2M and royalties on sales in Canada. Knight to get exclusive commercialization rights for Nerlynx and will also be responsible for its regulatory approvals in Canada
- In July- 2018 Puma has filled Nerlyn’s NDA to Health Canada for the treatment of early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy in adults
- Nerlynx (neratinib) is a tyrosine kinase inhibitor anticancer drug and has received the US FDA approval in July 2017- for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy in adults
Ref: Puma Biotechnology | Image: ValueWalk
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
